Spotlight on Q1 Pharma M&A Merry-Go-Round
Executive Summary
Q1 2019 saw a jump in merger and acquisition activity. Informa’s Biomedtracker has cast an analytical eye on three of the major deals, namely buys by Roche, Lilly and BMS.
You may also be interested in...
Deal Watch: Vertex Expands Gene-Editing Efforts With A Pair Of Deals
CF-focused Vertex will buy Exonics and expand a collaboration with CRISPR Therapeutics, with plans to develop therapies for DMD and myotonic dystrophy type 1. Merck acquires TGFβ-focused Tilos, while Achaogen offloads most of its assets at auction.
BioMarin Says It's Got The Hemophilia Therapy Data For Approval And Value
The company will begin discussions with regulators in the US and Europe for a gene therapy for hemophilia A based on the results of new data, with a launch targeted for late 2020. Durability remains a question.
As Expected: Shareholders Back Bristol's $74bn Celgene Buy
With no more activist investor challenge, shareholders of both companies overwhelmingly approved the deal. Bristol said it will have leading positions in oncology and cardiovascular disease, and gain five potential blockbusters in the Celgene buyout.